

22 February 2022

\$1.4m Share Placement

Highlights

- **Placement at a price of 0.3 cents to raise \$1.4m before costs**
- **Participants to receive a 1:1 attaching option at 0.5 cents**
- **Proceeds from placement to fund expansion of probiotics product range**

EVE Health Group (ASX:EVE, EVE or the Company), a vertically integrated health, nutrition, and wellness company, advises that it has received firm commitments to raise \$1.4m, before costs, via a placement to institutional and professional investors at \$0.003 per share. 466,666,667 new fully paid ordinary shares will be issued under the Company's listing rule 7.1 capacity. Participants will also receive a 1 for 1 attaching option exercisable at \$0.005 per share with a 2-year expiry, to be issued subject to shareholder approval at a forthcoming shareholder meeting.

Funds from the capital raising will be used to support the expansion and development of the Meluka Australia probiotics range, marketing supporting for product launches as well as expansion of distribution channels in Australia, the US and Japan.

Documentation for the shareholder meeting to approve the options will be distributed to shareholders in due course.

Authorised for release by Bill Fry, Managing Director.

— ENDS —

For more information, please contact:

Company enquiries

Bill Fry, Managing Director & CEO
EVE Health Group Ltd
+61 8 6465 5500
billf@evehealthgroup.com.au

About EVE Health Group

EVE Health Group, (ASX: EVE) is a leading, vertically integrated producer of branded nutrition, health and wellness products. The Company has global reach and application to fast-growing markets across Australia and New Zealand, Asia Pacific and North America. Our mission is to create high quality, innovative, natural and sustainable health and wellness products that help the wellbeing of consumers and in turn help our people, shareholders and community prosper.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn or Twitter.